{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:22:19Z","timestamp":1760887339004},"reference-count":47,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Epidemic and endemic meningitis caused by group A<jats:italic>Neisseria meningitidis<\/jats:italic>remains a problem in sub-Saharan Africa. Although group A meningococcal capsular polysaccharide (GAMP) vaccine confers immunity at all ages, the improved immunogenicity of a conjugate and its compatibility with the World Health Organization's Extended Program on Immunization offers advantages over GAMP alone. Conjugates of GAMP bound to bovine serum albumin (BSA) were synthesized, characterized, and evaluated for their immunogenicities in mice. Two methods, involving adipic acid dihydrazide (ADH) as a linker, were used. First, ADH was bound to GAMP activated with cyanogen bromide (CNBr) or with 1-cyano-4(dimethylamino)-pyridinium tetrafluoroborate (CDAP) to form GAMP<jats:sub>CNBr<\/jats:sub><jats:italic>AH<\/jats:italic>and GAMP<jats:sub>CDAP<\/jats:sub><jats:italic>AH<\/jats:italic>. These derivatives were bound to BSA by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) to form GAMP<jats:sub>CNBr<\/jats:sub><jats:italic>AH<\/jats:italic>-BSA and GAMP<jats:sub>CDAP<\/jats:sub><jats:italic>AH<\/jats:italic>-BSA. Second, ADH was bound to BSA with EDC to form<jats:italic>AH<\/jats:italic>BSA.<jats:italic>AH<\/jats:italic>BSA was bound to activated GAMP to form GAMP<jats:sub>CNBr<\/jats:sub>-<jats:italic>AH<\/jats:italic>BSA and GAMP<jats:sub>CDAP<\/jats:sub>-<jats:italic>AH<\/jats:italic>BSA. The yield of GAMP<jats:sub>CDAP<\/jats:sub>-<jats:italic>AH<\/jats:italic>BSA (35 to 40%) was higher than those of the other conjugates (5 to 20%). GAMP conjugates elicited immunoglobulin G (IgG) anti-GAMP in all mice after three injections of 2.5 or 5.0 \u03bcg of GAMP: the geometric mean (GM) was highest in recipients of GAMP<jats:sub>CDAP<\/jats:sub>-<jats:italic>AH<\/jats:italic>BSA (11.40 enzyme-linked immunosorbent assay units). Although the difference was not statistically significant, the 5.0-\u03bcg dose elicited a higher GM IgG anti-GAMP than the 2.5-\u03bcg dose. Low levels of anti-GAMP were elicited by GAMP alone. GAMP<jats:sub>CDAP<\/jats:sub>-<jats:italic>AH<\/jats:italic>BSA elicited bactericidal activity roughly proportional to the level of IgG anti-GAMP.<\/jats:p>","DOI":"10.1128\/iai.71.9.5115-5120.2003","type":"journal-article","created":{"date-parts":[[2003,8,21]],"date-time":"2003-08-21T21:40:43Z","timestamp":1061502043000},"page":"5115-5120","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Preparation and Characterization of Group A Meningococcal Capsular Polysaccharide Conjugates and Evaluation of Their Immunogenicity in Mice"],"prefix":"10.1128","volume":"71","author":[{"given":"Zhigang","family":"Jin","sequence":"first","affiliation":[{"name":"Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiayung","family":"Chu","sequence":"additional","affiliation":[{"name":"Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Robbins","sequence":"additional","affiliation":[{"name":"Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Schneerson","sequence":"additional","affiliation":[{"name":"Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111976"},{"key":"e_1_3_2_3_2","first-page":"53","volume":"173","year":"1986","unstructured":"Bax, A., M. F. Summers, N. Guirgis, R. Schneerson, J. B. Robbins, F. \u00d8rskov, I. \u00d8rskov, W. F. Vann, and W. Egan. 1986. Structural studies of the Escherichia coli K93 and K53 capsular polysaccharides. Carbohydr. Res.173:53-64.","journal-title":"Carbohydr. Res."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.7.3707-3713.2002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(83)90010-5"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1568-1573.2001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/345763"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200002000-00013"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)65284-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.40.1.245-256.1983"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90091-W"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/6.5.640"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/514063"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.58.7.2309-2312.1990"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/140.5.690"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/138.6.731"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880005233X"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.162.6.1837"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4049\/jimmunol.127.3.1011","volume":"127","year":"1981","unstructured":"Jennings, H. J., and C. Lugowski. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol.127:1011-1018.","journal-title":"J. Immunol."},{"key":"e_1_3_2_21_2","unstructured":"Kabat E. and M. Mayer. 1971. Experimental immunochemistry p. 493-495. Charles C. Thomas Springfield Ill."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(83)80905-3"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.7.2709-2715.1996"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.9.5037-5043.2000"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.1.200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00195-7"},{"key":"e_1_3_2_27_2","first-page":"617","volume":"11","year":"1992","unstructured":"Lennon, D., B. Gellin, D. Hood, L. Voss, H. Heffernan, and S. Thakur. 1992. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J.11:617-623.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(02)90089-1"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.4.2161-2166.2000"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.4049\/jimmunol.146.12.4308","volume":"146","year":"1991","unstructured":"Peeters, C. C., A. M. Tenbergen-Meekers, D. E. Evenberg, J. Poolman, B. J. M. Zegers, and G. T. Rijkers. 1991. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J. Immunol.146:4308-4314.","journal-title":"J. Immunol."},{"key":"e_1_3_2_32_2","first-page":"686","volume":"297","year":"1997","unstructured":"Peltola, H., P. H. M\u00e4kel\u00e4, H. K\u00e4yhty, H. Jousimies, E. Herva, K. H\u00e4llstr\u00f6m, A. Sivonen, O.-V. Renkonen, O. Pettay, V. Karanko, P. Ahvonen, and S. Sarna. 1997. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med.297:686-691.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_33_2","first-page":"83","volume":"16","year":"1988","unstructured":"Pichichero, M. E., S. Porcelli, J. Treanor, and P. Anderson. 1988. Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type-6A-protein conjugate vaccines of differing saccharide chain lengths. Vaccine16:83-91.","journal-title":"Vaccine"},{"key":"e_1_3_2_34_2","unstructured":"Plikaytis B. D. P. F. Holder and G. M. Carlone. 1996. Program ELISA for Windows: user's manual 12 version 1.00. Centers for Disease Control and Prevention Atlanta Ga."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540140069031"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200010000-00001"},{"key":"e_1_3_2_37_2","first-page":"161","volume":"95","year":"1998","unstructured":"Robbins, J. B., R. Schneerson, S. C. Szu, D. A. Bryla, F.-Y. Lin, and E. C. Gotschlich. 1998. Standardization may suffice for licensure of conjugate vaccines. Dev. Biol. Stand.95:161-167.","journal-title":"Dev. Biol. Stand."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03227-3"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.152.2.361"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00383-2"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.57.12.3823-3827.1989"},{"key":"e_1_3_2_42_2","first-page":"43","volume":"55","year":"1977","unstructured":"Tiesjema, R. H., E. C. Beuvery, and B. J. Te Pas. 1977. Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization. Bull. W. H. O.55:43-48.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.13.6.1654-1662.1976"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.5.2186-2192.1998"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-1157(77)80005-X"},{"key":"e_1_3_2_46_2","first-page":"50","volume":"594","year":"1976","unstructured":"World Health Organization. 1976. Requirements for meningococcal polysaccharide vaccine. World Health Organ. Tech. Rep. Ser.594:50-75.","journal-title":"Tech. Rep. Ser."},{"key":"e_1_3_2_47_2","first-page":"297","volume":"74","year":"1999","unstructured":"World Health Organization. 1999. Group A and C meningococcal vaccines. Wkly. Epidemiol. Rec.74:297-304.","journal-title":"Wkly. Epidemiol. Rec."},{"key":"e_1_3_2_48_2","first-page":"282","volume":"76","year":"2001","unstructured":"World Health Organization. 2001. Epidemics of meningococcal disease, African meningitis belt, 2001. Wkly. Epidemiol. Rec.76:282-288.","journal-title":"Wkly. Epidemiol. Rec."}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.71.9.5115-5120.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.71.9.5115-5120.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T20:48:27Z","timestamp":1682542107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.71.9.5115-5120.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1128\/IAI.71.9.5115-5120.2003"],"URL":"https:\/\/doi.org\/10.1128\/iai.71.9.5115-5120.2003","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]},"assertion":[{"value":"2003-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}